Highlights
About
Oncology Therapeutic Pharmaceutical Candidates
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The company's pipeline currently consists of BL-8040, a platform for multiple cancer and hematological indications; and AGI-134, a synthetic immunotherapy in development for solid tumors.
The BioLineRx pipeline is generated by systematically identifying, validating, and in-licensing therapeutic candidates with advantages over current therapies or that address unmet medical needs.
BioLineRx also works with Novartis on the codevelopment of selected Israel-sourced novel drug candidates and has recently signed a collaboration agreement with MSD (known as Merck in the United States and Canada) to run a phase-2a study in pancreatic cancer using a combination of BL-8040 and Merck's Keytruda.
BioLineRx has received the FDA biological product designation for its novel cancer immunotherapy candidate AGI-134. In January 2020, the company announced that the European Commission had granted orphan drug designation to its lead oncology candidate, Motixafortide (BL-8040), for the treatment of pancreatic cancer.
Identity
| Name | BiolineRx |
|---|---|
| Slug | biolinerx |
| Type / kind | startup |
| Crunchbase ID | biolinerx |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6Yo8UIDA |
Status
| Status | active |
|---|---|
| Status reason | Public on TASE on Apr, 2007;Public on NASDAQ on Mar, 2014; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Modi'in-Maccabim-Re'ut |
| HQ address | HaMa'ayan Street 2, Modi'in-Maccabim-Re'ut, Israel |
Web & social
Classifications
Funding
| Total raised | $208.6M |
|---|---|
| Current stage | Public |
| Market cap | $13.1M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}